Orserdu Dosage & Drug Information

Concise Prescribing Info

Contents

Elacestrant diHCl

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Indications/Uses

Monotherapy for postmenopausal women & men w/ estrogen receptor (ER) +ve, HER2 -ve, locally advanced or metastatic breast cancer w/ activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK 4/6 inhibitor.

Dosage/Direction for Use

345 mg daily. Max daily dose: 345 mg. Concomitant use w/ strong CYP3A4 inhibitor 86 mg once daily. Concomitant use w/ moderate CYP3A4 inhibitor 172 mg once daily. May be reduced to 86 mg once daily.

Administration

Should be taken with food: Swallow whole, do not chew/crush/split.

Contraindications

Hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L02BA04 - elacestrant ; Belongs to the class of anti-estrogens. Used in treatment of neoplastic diseases.

Regulatory Classification

POM

Presentation/Packing

Form

Orserdu FC tab 345 mg

Packing/Price

1's

Orserdu

Manufacturer:

A. Menarini Singapore Pte. Ltd.